Israeli AI-assisted colonoscopy technology has been given the seal of approval from the internationally respected Lancet Digital Health journal, following an extensive study of its capabilities.

The novel polyp detection system developed by Haifa-based MAGENTIQ-EYE was studied by the Lancet over a 14-month period at 10 leading medical centers around the world, involving 31 endoscopists and 952 patients.

The study, titled “A computer-aided polyp detection system in screening and surveillance colonoscopy: an international, multicentre, randomised, tandem trial,” found that the MAGNETIQ-EYE platform increases the average detection rate for adenoma (non-cancerous or pre-cancerous tumors) by 7 percent, and had a 17-percent lower rate of missed detection of adenoma.

“We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research,” said Dror Zur, founder and CEO of MAGENTIQ EYE.

Keep reading at

MAGNETIQ-EYE CEO Dror Zur is a Technion alumnus.